# Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)

> **NCT00770315** · PHASE2,PHASE3 · COMPLETED · sponsor: **ALK-Abelló A/S** · enrollment: 784 (actual)

## Conditions studied

- Rhinitis, Allergic
- Conjunctivitis

## Interventions

- **BIOLOGICAL:** Ambrosia artemisiifolia allergen extract (Amb a 1-U)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00770315
- **Lead sponsor:** ALK-Abelló A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 784 (ACTUAL)
- **Last updated:** 2017-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00770315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00770315, "Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00770315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*